Response and relapse rates of Candidal esophagitis in HIV-infected patients treated with Caspofungin

AIDS Research and Human Retroviruses

Volumn 18, Issue 13, 2002, Pages 903-908

  DiNubile, Mark J ^a   Lupinacci, Robert J ^a   Berman, Rayanne S ^a   Sable, Carole A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; ENDOSCOPY; ESOPHAGITIS; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REGRESSION ANALYSIS; RESPONSE TIME; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CANDIDIASIS; DOUBLE-BLIND METHOD; ESOPHAGEAL DISEASES; ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036385646     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202760265579     Document Type: Article

References (28)

1. Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren ML, Holmberg S, and Jones JL: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000;30(Suppl 1):55-14.
2. Centers for Disease Control and Prevention: Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR 1999:10;48(RR-13):1-27, 29-31.
3. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, and Kauffman CA: Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-346.
4. Rex JH, Walsh, TJ, Sobel JD, Filler, SG, Pappas PG, Dismukes WE, and Edwards JE: Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-678.
5. Masia CM, Guiterrez RF, Ortiz de la Tabla DV, Hernandez I, Martin GC, Sanchez SA, and Martin HA: Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2000;19:593-601.
6. Ruhnke M, Eigler A, Tennagen I, Geiseler B, Engelmann E, and Tratumann M: Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J Clin Microbiol 1994;32:2092-2098.
7. Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, and Vigilante K: Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-686.
8. Revankar SG, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Redding SW, and Patterson TF: Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;26:960-963.
9. Martins MD, Lozano-Chiu M, and Rex JH: Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997;25:843-846.
10. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, and Patterson TF: Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 1996;174:821-827.
11. Laguna F, Rodriguez-Tudela JL, Martinez-Suarez JV, Polo R, Valencia E, Diaz-Guerra TM, Dronda F, and Pulido F: Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis 1997;24:124-130.
12. Bouchara JP, Zouhair R, Le Boudouil S, Renier G, Filmon R, Chabasse D, Hallet JN, and Defontaine A: In-vivo selection of an azole-resistant petite mutant of Candida glabrata. J Med Microbiol 2000;49:977-984.
13. Lacassin F, Damond F, Chochillon C, Longuet P, Lebras J, Vilde JL, and Leport C: Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: Pharmacological and mycological factors. Antimicrob Agents Chemother 1996;40:1961-1963.
14. Landman D, Saurina G, and Quale JM: Failure of all antifungal therapy for infection due to Candida albicans: A new AIDS-related problem? Clin Infect Dis 1998;26:183-184.
15. Andriole VT: Current and future antifungal therapy: New targets for antifungal agents. J Antimicrob Chemother 1999;44:151-162.
16. Douglas CM, D'Ippolito JA, Shei GJ, Meinz M, Onishi J, Marrinan JA, et al: Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997;41:2471-2479.
17. Barchiesi F, Schimizzi AM, Fothergill AW, Scalise G, and Rinaldi MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis 1999;18:302-304.
18. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, and Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candida esophagitis. Clin Infect Dis 2001; 33:1529-1535.
19. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, and Sable CA: A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngea l and esophageal candidiasis. Antimicrobial Agents Chemother 2002;46:451-457.
20. Villanueva A, Gotuzzo E, Arathoon E, Noriega LM, Kartsonis N, Lupinacci R, Smietana J, Berman RS, DiNubile MJ, and Sable CA: The efficacy, safety, and tolerability of caspofungin vs. fluconazole in the treatment of esophageal candidiasis. Presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001.
21. Martinex-Suarez JV and Rodriguez-Tudela JL:In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996;40:1277-1279.
22. Vazquez JA, Lynch M, Boikov D, and Sobel JD: In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1612-1614.
23. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, et al.: In vitro susceptibilities ofCandida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;37:870-872.
24. Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, and Lopez-Ribot JL: In vitro activity of Cancidas™ (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. Presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000.
25. Kartsonis N, Bartizal K, Hicks PS, Ryan D, DiNubile MJ, and Sable CA: Caspofungin (CA) For fluconazole (FLU)-resistant esophageal candidiasis. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America, October, San Francisco, California, 2001.
26. Cauda R, Tacconelli E, Tumbarello M, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: A prospective case-control study. J AIDS 1999;21: 20-25.
27. Cassone A, De Bernardis F, Torosantucci A, et al.: In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999;180:448-453.
28. Sable CA, Nguyen B-Y, Chodakewitz, JA, and DiNubile MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002;4:25-30.